1.Ongoing rubella epidemic in Osaka, Japan, in 2018–2019
Daiki Kanbayashi ; Takako Kurata ; Hideyuki Kubo ; Seiji Yamamoto ; Kazutaka Egawa ; Yuki Hirai ; Kazuma Okada ; Ryo Ikemori ; Takahiro Yumisashi ; Akira Yamamoto ; Hideki Yoshida ; Takanori Hirayama ; Kazuyoshi Ikuta ; Kazushi Motomura ; Atsushi Kaida
Western Pacific Surveillance and Response 2020;11(2):48-50
Abstract
A large rubella epidemic is currently ongoing since 2018 in Osaka, Japan. The detected rubella viruses were classified into genotypes 1E lineage 2 and 2B lineage 1. These strains may have been imported from endemic countries, and these viruses spread within the susceptible population.
2.Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan.
Emma Nakagawa HOFFMAN ; Haruna KAWACHI ; Atsushi HIRAYAMA ; Jingwen ZHANG ; Ayumi MURAYAMA ; Jun MASUI ; Satomi FUJITA ; Yasushi MORI ; Takanori HIRAYAMA ; Toshitake OHARA ; Rumiko ASADA ; Hiroyasu ISO
Environmental Health and Preventive Medicine 2021;26(1):115-115
BACKGROUND:
We investigated factors associated with prolonged viral clearance of SARS-CoV-2 among non-severe adult patients in Osaka, Japan. A total of 706 laboratory-confirmed COVID-19 patients were enrolled in this longitudinal observational study between 29 January 2020 and 31 May 2020, across 62 hospitals and three non-hospital recuperation facilities.
METHODS:
Logistic regression analysis was performed to investigate the factors associated with prolonged (29 days: upper 25% in duration) viral clearance of SARS-CoV-2. Linear regression analysis was conducted to assess these factors 14 days after symptom onset.
RESULTS:
The median duration of viral clearance was 22 days from symptom onset. After adjustment for sex, age, symptoms, comorbidity, and location of recuperation, comorbidities were associated with prolonged duration: (OR, 1.77 [95% CI, 1.11-2.82]) for one, (OR, 2.47 [95% CI, 1.32-4.61]) for two or more comorbidities. Viral clearance 14 days after symptom onset was 3 days longer for one comorbidity and 4 days longer for two or more comorbidities compared to clearance when there was no comorbidity.
CONCLUSION
The presence of comorbidity was a robust factor associated with a longer duration of viral clearance, extending by 3 to 4 days compared to patients with no comorbidity.
Adult
;
COVID-19
;
Humans
;
Japan/epidemiology*
;
RNA, Viral
;
SARS-CoV-2
;
Virus Shedding